journal
MENU ▼
Read by QxMD icon Read
search

Journal of Viral Hepatitis

journal
https://www.readbyqxmd.com/read/28544398/prediction-of-long-term-clinical-outcome-in-a-diverse-chronic-hepatitis-b-population-role-of-the-page-b-score
#1
Willem P Brouwer, Adriaan J van der Meer, Andre Boonstra, Elisabeth P C Plompen, Suzan D Pas, Robert J de Knegt, Rob A de Man, Fiebo J W Ten Kate, Harry L A Janssen, Bettina E Hansen
BACKGROUND & AIMS: An abundance of non-invasive scores have been associated with fibrosis and hepatocellular carcinoma (HCC) development. We aimed to compare the prognostic ability of these scores in relation to liver histology in chronic hepatitis B (CHB) patients. METHODS: Liver biopsies from treatment-naïve CHB patients at one tertiary care centre were scored by a single hepato-pathologist. Laboratory values at liver biopsy were used to calculate the PAGE-B, REACH-B, GAG-HCC, CU-HCC, and FIB-4 scores...
May 24, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28544048/use-of-electronic-health-record-clinical-decision-support-tool-for-hcv-birth-cohort-screening
#2
David N Fitch, Ajay Dharod, Claudia L Campos, Marina Núñez
The United States Preventive Services Task Force (USPSTF) recommended one-time HCV testing for all patients in the 1945-1965 birth cohort, given the high hepatitis C virus (HCV) prevalence in this group [1]. In response, various interventions differing in complexity and cost have been developed. Goel et al, evaluated a multifaceted intervention sequentially implemented and report poor response to the electronic health record (EHR) alert and a very successful HCV screening, increased by 137%, after adding other tools including physician education, data feedback, and patient navigation [2]...
May 24, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28504854/the-risk-of-early-occurrence-and-recurrence-of-hepatocellular-carcinoma-in-hepatitis-c-infected-patients-treated-with-direct-acting-antivirals-with-and-without-pegylated-interferon-a-belgian-experience
#3
Bielen Rob, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixco, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Lode Van Overbeke, Christophe Van Steenkiste, Francois D'Heygere, Mike Cool, Katrien Wuyckens, Frederik Nevens, Geert Robaeys
Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within six months after treatment with DAA with or without Pegylated Interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score ≥ B were excluded...
May 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28502092/hiv-hcv-co-infection-and-the-risk-of-cardiovascular-disease-a-meta-analysis
#4
Olatokunbo Osibogun, Oluseye Ogunmoroti, Erin D Michos, Erica S Spatz, Babatunde Olubajo, Khurram Nasir, Purnima Madhivanan, Wasim Maziak
The emergence of improved antiretroviral therapy has increased the life expectancy of human immunodeficiency virus (HIV)-infected individuals, though there is an increased susceptibility to developing cardiovascular diseases (CVD). The risk for CVD is purported to be even higher among people with HIV and hepatitis C virus (HCV) co-infection because of the increased inflammatory response, which may synergistically impact CV risk; however, studies comparing CV outcomes between HIV alone and HIV/HCV individuals have been discordant...
May 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28502088/limited-impact-of-awareness-raising-campaigns-on-hepatitis-c-testing-practices-among-general-practitioners
#5
A McLeod, B L Cullen, S J Hutchinson, K M Roy, J F Dillon, E A Stewart, D J Goldberg
The global hepatitis strategy calls for increased effort to diagnose those infected, with a target of 90% diagnosed by 2030. Scotland's Action Plan on Hepatitis C included awareness-raising campaigns, undertaken during 2008-2011, to promote testing by General Practitioners. We examined HCV testing practice among general practitioners before and following these campaigns. Scottish general practitioners were surveyed, using Dillman's method, in 2007 and 2013; response rates were 69% and 60%, respectively. Most respondents offer testing when presented with a risk history (86% in 2007, 88% in 2013) but only one fifth actively sought out risk factors (19 in 2007, 21% in 2013)...
May 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28499070/higher-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-vs-chronic-hepatitis-c-after-achievement-of-virologic-response
#6
Gi-Ae Kim, Seungbong Han, Hyung-Don Kim, Jihyun An, Young-Suk Lim
It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analyzed data from patients with CHB treated with entecavir (n=2000) or CHC treated with peg-interferon and ribavirin (n=733) at a tertiary hospital from 2004 through 2011. Virological response was defined as serum HBV DNA <15 IU/mL at 1 year of treatment for CHB or the achievement of sustained virologic response for CHC...
May 12, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28480525/real-world-effectiveness-of-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-in-patients-with-hcv-genotype-1-or-4-infection-a-meta-analysis
#7
Heiner Wedemeyer, Antonio Craxí, Eli Zuckerman, Douglas Dieterich, Robert Flisiak, Stuart K Roberts, Andreas Pangerl, Zhenzhen Zhang, Marisol Martinez, Yanjun Bao, José-Luis Calleja
The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. Freeman-Tukey transformation determined the SVR rate within GTs 1a, 1b, and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status...
May 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28475247/exploration-of-potential-mechanisms-of-hcv-resistance-in-exposed-uninfected-intravenous-drug-users
#8
Isaac Thom Shawa, Daniel J Felmlee, Doha Hegazy, David A Sheridan, Matthew E Cramp
A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as clinically measured by HCV RNA or HCV recognising antibodies. The population who exhibit this trait is termed exposed uninfected (EU). Increasing evidence has refined characterisation of these individuals, distinct from those who become infected but spontaneously clear HCV. Study of the EU population is highly pertinent for the discovery of antiviral mechanisms of resistance that can reveal antiviral therapeutic strategies...
May 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28475232/safety-and-efficacy-of-sofosbuvir-based-daa-regimens-for-hepatitis-c-virus-genotypes-1-4-and-6-in-myanmar-real-world-experience
#9
Naomi Khaing Than Hlaing, Robert A Mitrani, Soe Thu Aung, Wai Wai Phyo, Marina Serper, A Mi Mi Kyaw, Aung Hlaing Bwa, Khin Maung Win, K Rajender Reddy
This open-label, clinical experience investigated the safety and efficacy of direct-acting antiviral (DAA) Hepatitis C Virus (HCV) therapy in Myanmar. 344 patients completed treatment between June 2015 and May 2016. Patients with HCV genotypes 1 - 4 and 6 received one of four treatments: (1) Peg-interferon (PEG-IFN) + Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks, (2) SOF + RBV for 24 weeks, (3) Ledipasvir (LDV) + SOF for 12 weeks, or (4) Daclatasvir (DCV) + SOF + RBV for 12 or 24 weeks. Genotype 3 was most common (n = 133, 38...
May 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28470815/efficacy-of-12-or-18-weeks-of-elbasvir-plus-grazoprevir-with-ribavirin-in-treatment-na%C3%A3-ve-non-cirrhotic-hcv-genotype-3-infected-patients
#10
Edward Gane, Ronald Nahass, Velimir Luketic, Ernest Asante-Appiah, Peggy Hwang, Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber
Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically infected with HCV genotypes 1 and 4. During the development program and supported by in vitro potency, the efficacy of EBR + GZR was assessed in HCV GT3-infected patients. This study's aim was to determine the efficacy and tolerability of 12 or 18 weeks of EBR+GZR with ribavirin (RBV) in treatment-naïve, non-cirrhotic HCV GT3-infected patients. Randomized patients received open-label EBR (50 mg once daily) + GZR (100 mg once daily) + RBV...
May 4, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28439936/hiv-positive-men-who-have-sex-with-men-are-at-high-risk-of-development-of-significant-liver-fibrosis-after-an-episode-of-acute-hepatitis-c
#11
K Steininger, A Boyd, S Dupke, I Krznaric, A Carganico, M Munteanu, S Neifer, M Schuetze, M Obermeier, K Arasteh, A Baumgarten, P Ingiliz
Acute hepatitis C virus infection remains a major health concern in human immunodeficiency virus(HIV)-infected men who have sex with men (MSM). New direct-acting antiviral agent (DAA) combination therapy has not yet been approved for the treatment for acute hepatitis C virus(HCV), thereby potentially causing deferral of HCV treatment. Therefore, we aimed to study the course of liver disease after an episode of acute HCV. This study is a retrospective single-centre cohort of HIV-positive MSM with acute HCV infection...
April 25, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28429836/increased-levels-of-soluble-hla-g-molecules-in-tunisian-patients-with-chronic-hepatitis-b-infection
#12
Ahmed Baligh Laaribi, Daria Bortolotti, Naila Hannachi, Asma Mehri, Olfa Hazgui, Hamza Ben Yahia, Wafa Babay, Manel Belhadj, Houda Chaouech, Salwa Yacoub, Amel Letaief, Imene Ouzari, Abdellatif Boudabous, Dario Di Luca, Jalel Boukadida, Roberta Rizzo, Ines Zidi
Hepatitis B virus (HBV) infection is a global health problem. The mechanisms of immune tolerance in HBV infection are still unclear. The host immune response plays a critical role in determining the outcome of HBV infection. Human leukocyte antigen-G (HLA-G) is involved in immunotolerogenic process and infectious diseases. The present study aimed to explore the implication of soluble HLA-G (sHLA-G) and its isoforms in HBV infection. Total sHLA-G (including shedding HLA-G1 and HLA-G5) was analysed by ELISA in 95 chronic HBV patients, 83 spontaneously resolvers and 100 healthy controls...
April 21, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28419755/a-diagnostic-algorithm-for-assessment-of-liver-fibrosis-by-liver-stiffness-measurement-in-patients-with-chronic-hepatitis-b
#13
Yi-Jing Cai, Jia-Jia Dong, Xiao-Dong Wang, Si-Si Huang, Rui-Cong Chen, Yi Chen, Yu-Qun Wang, Mei Song, Yong-Ping Chen, Zhuo Li, Meng-Tao Zhou, Ke-Qing Shi
Steatosis could affect liver stiffness measurement in patients with nonalcoholic fatty liver disease and chronic hepatitis C. In the current study, we aimed to investigate the impact of steatosis on liver stiffness in chronic hepatitis B virus infected patients and develop a diagnostic algorithm for prediction of liver fibrosis by liver stiffness based on the controlled attenuation parameter. A total of 488 HBV infected patients who underwent clinical examination, FibroScan and liver biopsy were prospectively enrolled...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28419653/hcv-viraemia-associates-with-nk-cell-activation-and-dysfunction-in-antiretroviral-therapy-treated-hiv-hcv-co-infected-subjects
#14
E Papasavvas, L Azzoni, X Yin, Q Liu, J Joseph, A Mackiewicz, B Ross, K M Lynn, J M Jacobson, K Mounzer, J R Kostman, L J Montaner
The impact of hepatitis C virus (HCV) RNA levels on immune status in chronically HCV mono-infected when compared to HIV/HCV co-infected on antiretroviral therapy (ART) remains poorly understood. A total of 78 African American subjects HCV viraemic/naïve to HCV treatment (33 HCV genotype 1 mono-infected, 45 ART-treated HIV/HCV genotype 1 co-infected) were studied. Clinical and liver enzyme measurements were performed. Whole blood was analysed for immune subset changes by flow cytometry. Peripheral blood mononuclear cells (PBMC) were used for same-day constitutive and in vitro Interferon (IFN)-α-induced signal transducer and activator of transcription (STAT) phosphorylation, K562 target cell lysis and K562 target cell recognition-mediated IFN-γ production...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28414896/nk-cells-in-self-limited-hcv-infection-exhibit-a-more-extensively-differentiated-but-not-memory-like-repertoire
#15
Rik A de Groen, Zwier M A Groothuismink, Gertine van Oord, Neeltje A Kootstra, Harry L A Janssen, Maria Prins, Janke Schinkel, André Boonstra
Natural killer (NK) cells have long been thought of as a purely innate immune cell population, but increasing reports have described developmental and functional qualities of NK cells that are commonly associated with cells of the adaptive immune system. Of these features, the ability of NK cells to acquire functional qualities associated with immunological memory and continuous differentiation resulting in the formation of specific NK cell repertoires has recently been highlighted in viral infection settings...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28414893/impact-of-viral-hepatitis-etiology-on-survival-outcomes-in-hepatocellular-carcinoma-a-large-multi-center-cohort-study
#16
Sara Mgaieth, William Kemp, Paul Gow, Michael Fink, John Lubel, Amanda Nicoll, Alessia Gazzola, Thai Hong, Marno Ryan, Virginia Knight, Anouk Dev, Siddharth Sood, Sally Bell, Eldho Paul, Stuart K Roberts
BACKGROUND AND AIMS: While HBV and HCV are risk factors for HCC, uncertainty exists as to whether these viral infections have prognostic significance in HCC. Thus, we compared the overall survival of patients with HBV, HCV, and non-viral HCC, and evaluated whether the presence of HBV and HCV predicts patient outcomes. METHODS: We conducted a multi-center study of HCC cases diagnosed at six Melbourne tertiary hospitals between Jan 2000-Dec 2014. Patient demographics, liver disease and tumor characteristics, and patient outcomes were obtained from hospital databases, computer records and the Victorian Death Registry...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28375587/the-impact-of-hepatitis-b-virus-infection-and-vaccination-on-the-development-of-non-hodgkin-lymphoma
#17
Cih-En Huang, Yao-Hsu Yang, Yi-Yang Chen, Jung-Jung Chang, Ko-Jung Chen, Chang-Hsien Lu, Kuan-Der Lee, Pau-Chung Chen, Chih-Cheng Chen
BACKGROUND: Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. METHODS: We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997-2013. We compared the incidence and the risk of developing NHL and CD20(+) aggressive lymphoma between HBV and non-HBV cohorts...
April 4, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28370880/long-term-outcomes-of-direct-acting-antivirals-in-post-transplant-advanced-hepatitis-c-virus-recurrence-and-fibrosing-cholestatic-hepatitis
#18
R Vukotic, F Conti, S Fagiuoli, M C Morelli, L Pasulo, M Colpani, F G Foschi, S Berardi, P Pianta, M Mangano, M F Donato, F Malinverno, S Monico, M Tamè, G Mazzella, L S Belli, R Viganò, P Carrai, P Burra, F P Russo, I Lenci, P Toniutto, M Merli, L Loiacono, R Iemmolo, A M Degli Antoni, A Romano, A Picciotto, M Rendina, P Andreone
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatitis (FCH, n=21) received 24-week sofosbuvir with ribavirin±pegylated interferon or interferon-free sofosbuvir-based regimen with daclatasvir/simeprevir+ribavirin. The patients were observed for a median time of 103 (82-112) weeks...
March 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28345206/treatment-with-direct-acting-antiviral-agents-of-hepatitis-c-virus-infection-in-injecting-drug-users-a-prospective-study
#19
Lucio Boglione, Simone Mornese Pinna, Amedeo De Nicolò, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
In this prospective study, we evaluated the effectiveness and tolerability of novel therapies against hepatitis C virus (HCV) in a cohort of PWID enrolled at our centre from April 2015 to July 2016. In this analysis, a total of 174 patients were included: 11 (6.3%) were treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) containing regimens, 163 (93.7%) with IFN-free treatments. RBV has been used in 70 patients (40.2%); 59 (33.9%) patients were in opioid substitution therapy (OST) with methadone or buprenorphine...
March 26, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28345157/entecavir-maleate-versus-entecavir-in-chinese-chronic-hepatitis-b-predominantly-genotype-b-or-c-results-at-week-144
#20
Jing-Hang Xu, Sa Wang, Zhong-Nan Xu, Yan-Yan Yu, Chong-Wen Si, Zheng Zeng, Jun Li, Mao Qing, Da-Zhi Zhang, Hong Tang, Ji-Fang Sheng, Xin-Yue Chen, Qin Ning, Guang-Feng Shi, Qing Xie, Xi-Quan Zhang, Jun Dai
Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5mg/day entecavir (group A) or 0.5mg/day entecavir maleate (group B), then all patients received treatment with 0.5mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analyzed, predominantly (98...
March 26, 2017: Journal of Viral Hepatitis
journal
journal
32017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"